• Vaccine Ontology ID: VO_0011465
• Type: DNA vaccine
• Status: Research
• Antigen: Zaire Ebola virus GP and Sudan Ebola virus GP
• GP from Zaire ebolavirus gene engineering:
  • Type: DNA vaccine construction
  • Description: DNA/rAd5 vaccines expressing ZEBOV and SEBOV glycoprotein (GP) (Hensley et al., 2010).
  • Detailed Gene Information: Click Here.
• GP from Sudan ebolavirus gene engineering:
  • Type: DNA vaccine construction
  • Description: DNA/rAd5 vaccines expressing ZEBOV and SEBOV glycoprotein (GP) (Hensley et al., 2010).
  • Detailed Gene Information: Click Here.
• Vector: Replication-defective rAd5 GP vectors and p1012 (Hensley et al., 2010)
• Immunization Route: Intramuscular injection (i.m.)

Macaque Response

• Vaccination Protocol: DNA immunizations were administered by Biojector IM injection, bilateral deltoid, with a mixture of 2 mg each of two plasmid vectors encoding GP(Z) and GP(S/G). DNA immunizations were administered at 0, 4, 8, and 14 weeks. Each subject received a boost with 10^11 particle units (PU) of rAd5 GP(Z) at 12 months following the final DNA priming immunization (Hensley et al., 2010).
• Challenge Protocol: All animals were challenged by the intramuscular route with 1,000 TCID50 of BEBOV, 7 weeks post rAd5 GP boost. The challenge virus used in this study was isolated from blood specimen #200706291 from a fatal case infected during the 2007 EBOV outbreak in Bundibugyo district, Uganda. The virus was isolated on Vero E6 cells and passaged twice prior to initiating these experiments (Hensley et al., 2010).
• Efficacy: Vaccinated subjects developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV (Hensley et al., 2010).